AC Immune
ACIU | NASDAQ
$2.09
-$0.04 (-1.88%)
At close: Nov 16, 2026, 4:00 PM ET
$2.09
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-1.88%
(1D)No price chart data available for 1D timeframe.
Rating
43.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #425/1021 (Top 42%)
Key Statistics
Market Data
Market Cap $212.71M
1D Range
2.04 2.11
52W Range
2.04 3.70
Valuation (TTM)
PE -4.16
PB 6.60
EV/EBITDA -3.06
Valuation (NTM)
Forward PE 9.34
Forward PEG 0.11
Price Target $7.00
Cash Flow
FCF Yield -19.6%
SBC Adj. FCF Yield -21.0%
SBC Impact -7.5%
Margins
Gross Margin 100.0%
Operating Margin -190.8%
FCF Margin -176.4%
Growth (CAGR)
Revenue 3Y | 5Y 2606.0% |
83.8%
Dil EPS 3Y | 5Y 2.0% |
17.5%
FCF 3Y | 5Y -339.7% |
29.6%
Returns
ROA -25.9%
ROE -104.0%
ROIC -89.2%
Financial Health
Net Cash
CHF73.91M ($88.44M)
Current Ratio 0.85
Interest Coverage -166.76
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegen...
Sector Healthcare
Industry Biotechnology
Employees 106
IPO Date Sep 23, 2016
Website www.acimmune.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 4, 2026
EPS
-$0.16
Beat +11.10%
YoY:
+20.00% REV
$3.88M
Beat +139.22%
YoY:
+228.78%Next Earnings
Mar 12, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$7.00
Upside
+234.93%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ACIU